Back to Interventions
Substance / Medication

Avelumab

SNOMED 733055009UMLS C4055417

Overview

Active Ingredient
avelumab
RxNorm CUI
1875534
Labeler: EMD Serono, Inc.Updated: 2025-06-13T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Merkel cell tumour
Apudoma of skin

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis.
Barthélémy Philippe, Musat Mihaela G, Moradian Hoora et al. · Future Oncol · 2025
PMID: 40184226Meta-AnalysisFull text (PMC)
Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review.
Sharma Ajay N, Shah Karishma S, Sharma Aditi A et al. · Dermatol Surg · 2024
PMID: 38349855Meta-Analysis
Evaluation of the potential for QTc prolongation with avelumab.
Vugmeyster Yulia, Güzel Gülseren, Hennessy Meliessa et al. · Cancer Chemother Pharmacol · 2019
PMID: 31478078Meta-AnalysisFull text (PMC)
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.
Zandberg Dan P, Allred Jacob B, Rosenberg Ari J et al. · J Clin Oncol · 2025
PMID: 40448574RCTFull text (PMC)
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
Bellmunt Joaquim, Powles Thomas, Park Se Hoon et al. · Eur Urol · 2025
PMID: 40467365RCT
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.
Clark Amy S, Zhao Fengmin, Klein Paula et al. · Clin Cancer Res · 2025
PMID: 40300087RCTFull text (PMC)
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis.
Hoffman-Censits J, Tsiatas M, Chang P M-H et al. · Ann Oncol · 2025
PMID: 40456670RCT
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.
Gupta S, Climent Duran M A, Sridhar S S et al. · ESMO Open · 2025
PMID: 40107155RCTFull text (PMC)
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar Srikala S, Powles Thomas, Climent Durán Miguel Á et al. · Eur Urol · 2024
PMID: 37714742RCT
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.
Thuss-Patience Peter, Högner Anica, Goekkurt Eray et al. · JAMA Netw Open · 2024
PMID: 38261316RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Avelumab (substance)
SNOMED CT
733055009
UMLS CUI
C4055417
RxNorm CUI
1875534
Labeler
EMD Serono, Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.